Manufacturing, Biologic Drugs

Charles River Laboratories Launches LVV Packaging Plasmids

June 15, 2023

Charles River’s off-the-shelf lentiviral vector packaging plasmids are intended for use with cell and gene therapies.

WuXi Biologics Expands Manufacturing Capacity in Germany

June 01, 2023

WuXi Biologics is expanding its manufacturing capacity for drug substance and drug product at its sites in Leverkusen and Wuppertal, Germany.

Aseptic Processes Safeguard Biologics

May 15, 2023

Aseptic techniques must be practiced throughout all stages of biologics production.

Optimizing the Manufacture of Emerging Therapies

May 02, 2023

Guidance for GMP manufacture of emerging therapies has evolved to accommodate innovation and the broader spectrum of products in development, but greater harmonization is still needed.

Avid Bioservices Expands Mammalian Cell Capacity

April 14, 2023

Avid Bioservices has launched new CGMP mammalian cell manufacturing suites at its Myford, Calif., facility.

New Expansion for BalanCD CHO Media Platform Portfolio for Bioprocessing

April 12, 2023

The BalanCD CHO media portfolio is designed to ensure maximized growth, viability, and productivity of CHO cell lines.

Balancing Change and Certainty in Manufacturing

April 03, 2023

As new manufacturing processes and technologies are introduced to meet demand and overcome challenges, understanding also needs to improve to ensure the right balance is achieved.

Samsung Biologics to Build Plant 5 as Part of Capacity Expansion to Bio Campus II

March 21, 2023

Samsung Biologics plans to invest more than ₩1.9 trillion (US$1.5 billion) in the new Incheon, South Korea, facility, which will hold a manufacturing capacity of 180,000 L.

Sandoz to Build New Biologics Production Facility in Slovenia

March 17, 2023

Sandoz, a Novartis division, is expected to invest at least $400 million to build a new biologics manufacturing facility in Lendava, Slovenia, to support growing demand for biosimilars.

Catalent Licenses Bhami Research Laboratory Technology for Biologics Formulation Development

March 17, 2023

Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.